IOS Press has announced that 2018 marks the 20th anniversary of the Journal of Alzheimer's Disease (JAD). One of the many events celebrating this milestone is the publication of an open access issue (JAD 62:3) looking back at 20 years of Alzheimer's disease (AD) research, which is now available online.
JAD has had a significant impact on the advancement of AD research over the last 20 years, and the translation of that research into clinical practice. Since its launch in 1998, it has published more papers on AD than any other peer-reviewed journal and received more citations than any other AD-focused journal. It has embraced publication of emerging and sometimes controversial lines of research, many of which later gained wide acceptance.
This special issue, co-edited by Dr. George Perry, Dr. Jesús Avila and Dr. Xiongwei Zhu, features 35 specially commissioned review articles detailing 20 years of ground-breaking AD research, plus personal perspectives from key researchers in the field.
JAD is dedicated to advancing understanding of the physiological mechanisms underlying the disease and its prevention and treatment. The authoritative reviews in this special issue chronicle important breakthroughs and present the state of the art on significant topics including aging without dementia, biomarkers, genetics and epigenetics, amyloid peptides, tau proteins, mitochondria and mitochondrial cascades, oxidative stress, oligomers and inflammation, metals, AD as type 3 diabetes, the angiotensin hypothesis in AD, neuroimaging, translational medicine, emerging treatment options (successes and failures), immunotherapy, and optimised care.
The Journal of Alzheimer's Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behaviour, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. The Journal of Alzheimer's Disease (JAD) has an Impact Factor of 3.731 according to the 2016 Journal Citation Reports (Clarivate Analytics, 2017). JAD is published by IOS Press.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
